Tempus is often described as an AI company. That framing is understandable — the company has raised over $1B and its marketing leads with machine learning and clinical decision support. But I think it misidentifies where the value actually lives. Tempus is a data acquisition and infrastructure company that uses AI as a customer acquisition and retention mechanism. Understanding the distinction is the key to understanding both their strategy and their competitive moat.
What Tempus Actually Does
Tempus provides genomic sequencing services to oncology practices. A physician orders a Tempus test; Tempus sequences the tumor; the physician receives a clinical report with treatment implications and matched clinical trial options. The sequencing itself is a commoditized service — Foundation Medicine and Guardant Health offer comparable assays. What differentiates Tempus is what happens after the test: every sequenced case, along with the patient's de-identified clinical data from the partnered institution's EHR, flows into Tempus's unified data library. As of 2025, that library contains over 7 million de-identified patient records linked to multimodal data: genomic, imaging, pathology, and outcomes data.
This is the flywheel. Tempus provides sequencing to get access to clinical data. That data trains better AI models. Better models make the clinical reports more useful, which attracts more physician customers, which generates more sequencing revenue and more data. The AI is the product experience. The data is the moat.
Why the Moat Is Data Access, Not Algorithms
The algorithms Tempus uses — transformer-based models for report generation, survival prediction, treatment response modeling — are not proprietary in any durable sense. Any well-resourced competitor can train comparable models. What cannot be replicated in any reasonable timeframe is 7 million linked multimodal oncology records, accumulated over a decade of clinical partnerships and sequencing relationships. Foundation Medicine, the obvious benchmark comparison, has strong genomic data but lacks the EHR integration depth that makes Tempus's clinical data longitudinal. That longitudinality — knowing what happened to the patient after the test, not just what the tumor looked like — is what enables outcomes-based AI rather than just molecular characterization AI.
The product lesson here is one of the clearest I have seen in healthcare AI: in regulated markets with high switching costs and long data accumulation cycles, data access is the product. The AI features are the interface. Startups that try to compete by building better algorithms against players with 10x the data are bringing a sword to a gunfight.
What Startups Building in This Space Should Learn
The Tempus playbook only works if you can negotiate clinical data partnerships at scale, which requires regulatory infrastructure, BAA templates, institutional credibility, and a reimbursable service to offer in exchange for data access. Startups entering precision oncology typically cannot replicate this. The more defensible path is to identify a data asset that Tempus does not have — a specific indication, modality, or geography — and build a focused vertical. Tempus's current weakness is depth in any single indication: their breadth is impressive, but a startup with 50,000 cases in a single rare cancer type and deep clinical relationships in that community can build a more useful tool for that specific problem. Specialization beats breadth when the use case is narrow enough and the data is scarce enough.
